Current Report Filing (8-k)
August 16 2021 - 8:17AM
Edgar (US Regulatory)
0001442836
false
0001442836
2021-08-16
2021-08-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 16, 2021
MERSANA THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-38129
|
|
04-3562403
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
840 Memorial Drive
Cambridge, MA 02139
|
|
|
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number, including area code): (617) 498-0020
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, $0.0001 par value
|
MRSN
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 16, 2021, Mersana Therapeutics, Inc. (the “Company”)
announced that Michael Kaufman, Ph.D., will step down as the Company’s Chief Manufacturing Officer, effective immediately. Dr. Kaufman’s
employment will continue through September 10, 2021 to aid a smooth transition to his successor. Dr. Kaufman has agreed to consult
with the Company as an independent contractor from the date of his employment termination through July 31, 2022 (the “Consulting
Period”), during which time the Company will pay the premiums for Dr. Kaufman’s medical, dental, and vision coverage
if Dr. Kaufman elects to continue group medical, dental, and vision insurance coverage pursuant to the law known as “COBRA,”
and all stock options that are vested as of September 10, 2021, will remain exercisable in accordance with their terms until the
end of the third month after the end of the Consulting Period.
|
Item 7.01
|
Regulation FD Disclosure.
|
On August 16, 2021, the Company issued a press release announcing
the appointment of Tushar Misra, Ph.D., as Senior Vice President and Chief Manufacturing Officer, effective immediately. A copy of the
press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
MERSANA THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Brian DeSchuytner
|
|
|
Brian DeSchuytner
Senior Vice President, Finance & Product Strategy
|
Date: August 16, 2021
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024